toxylact: a04ad51 scopolamine combinations
The first professional lActological database in the word
Drugs in class A04AD51 are scopolamine-containing antiemetic combinations used mainly for motion sickness and nausea, but their use in pregnancy and breastfeeding requires careful risk–benefit assessment and dose limitation.medpedia.framar+6
ATC class and pharmacological profile
A04AD51 belongs to the ATC group “other antiemetics,” within the digestive system and metabolism class (A), covering scopolamine combinations formulated for prevention and treatment of nausea and vomiting. Scopolamine (hyoscine) is a belladonna alkaloid with potent antimuscarinic, anticholinergic effects that inhibits muscarinic receptors and modulates parasympathetic nervous system activity. These combinations may include scopolamine with other antiemetic or sedative agents, aiming at synergistic control of motion sickness, postoperative nausea, and sometimes vestibular and psychiatric indications.atcddd.fhi+5
Indications and clinical use
Scopolamine combinations are indicated for patients with nausea and vomiting, especially motion sickness and postoperative nausea and vomiting (PONV), where prophylactic use via transdermal systems is common. In some settings scopolamine is also used for premedication in anesthesia, as a sedative in psychiatric practice, and adjunctively in neurology (e.g. Parkinson’s disease) and ophthalmology for uveal inflammation and diagnostic pupillary dilation. Use should be individualized, with attention to comorbidities such as glaucoma and urinary retention, and restricted duration to limit anticholinergic toxicity.drugbank+2
Toxicology
Scopolamine combinations share the anticholinergic toxicity profile of scopolamine, including central effects (sedation, agitation, hallucinations, delirium, disorientation) and peripheral effects (dry mouth, tachycardia, mydriasis, decreased sweating, constipation, urinary retention). Overdose or heightened sensitivity may lead to severe anticholinergic syndrome with confusion, hyperthermia, flushed skin, and potential cardiovascular instability, requiring discontinuation and supportive care; physostigmine may be considered in selected severe cases. Contraindications include known hypersensitivity, angle‑closure glaucoma, significant urinary retention, and generally pregnancy, where safer antiemetics are preferred. Long‑term or high‑dose use can theoretically reduce gastrointestinal and salivary secretions, worsen constipation, and in susceptible individuals aggravate cognitive impairment, particularly in older patients.e-lactation+4
Use in pregnancy
Scopolamine and its combinations are not recommended as first‑line treatment for nausea and vomiting in pregnancy due to limited safety data and potential anticholinergic risks. Contemporary guidance advises avoiding scopolamine in pregnant patients and instead favoring agents with better established safety, such as doxylamine‑pyridoxine combinations, certain antihistamines, dopamine antagonists, or ondansetron in selected cases following specialist advice. If scopolamine must be used (e.g. severe refractory travel sickness where alternatives fail), it should be at the lowest effective dose for the shortest duration with obstetric oversight and explicit counseling about limited evidence.racgp+1
Use in lactation
Available data suggest that systemic exposure of breastfed infants to scopolamine is low, particularly with transdermal administration and modest maternal doses, and expert consensus considers occasional use compatible with breastfeeding. Hyoscine hydrobromide is regarded by some authorities as the preferred motion‑sickness medicine during breastfeeding when short‑term use is required, with emphasis on lowest effective dose and monitoring. Long‑term use may reduce milk production or let‑down via anticholinergic suppression of prolactin and oxytocin-mediated reflexes, so prolonged or high‑dose therapy should be avoided, and infants should be monitored for sleepiness, poor feeding, constipation, dry mouth, and reduced urine output. Use is generally discouraged in mothers of premature infants or those younger than about 2 months because of heightened susceptibility to anticholinergic adverse effects.sps+4
Practical toxicological‑lactological recommendations
For breastfeeding mothers requiring A04AD51 scopolamine combinations, occasional short‑term use at minimal effective doses is acceptable when clinically indicated, with close observation of the infant. Clinicians should avoid chronic therapy, carefully screen for contraindications (glaucoma, urinary retention, cognitive disorders), and consider alternative antiemetics with more robust safety data first. In pregnancy, scopolamine combinations should generally be avoided and reserved only for exceptional cases after a detailed risk–benefit discussion and consideration of guideline‑supported options.nhs+7



